1[1]Gohring UJ,Scharl A,Ahr A.Value of immunohistochemical determination of receptors,tissue proteases,tumor suppressor proteins and proliferation markers as progrostic indicators in primary breast carcinoma[J].Geburtshilfe Franenleilkd,1996,56(4):177—83.
2[2]Haerslev T,Jacobsen Gk,Zedeler K.Correlation of growth fraction by ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primiry breast carcinomas[J].Breast Cancer Res Trear,1996,37(2):101—13.
3[3]Nortilli R,Pelosi G.Ki-67 immunostaining in 322 primary breast cancers[J].Int J Cancer,1997,74(4):433—7.
4[4]Lura-more S,de los Samtos F,Bueton JJ,Canadas MA.Estrongen and progestre one receptors,c-erbB-2,p53,and Bcl-2 in thirty-three invasive micropapillary breast carcinomas[J].Pathol Res Pract,1996,192(1):27—32.
5[5]Biesterteld S,Schrider W,Steinhagen G,et al.Stimulaneous immuohistochemical and biochemical hormone recetor assessment in breast cancer provides complementery progroestic information[J].Anticancer Res Nov-Dee,1997,17(60):4723—4729.
6[6]Agthounr T,Mieke T,John AF.Differential expression of estrogen,progesterone and epiermal growth factor receptors in namal,benign and malignent human breast tissues using dual staining immunohistochemistry[J].Am J Putel,1994,144:11238—11245.
7[7]Michael J,Judy W.Epidermal growth factor receptor and C-erB-2 oncoprotein expression in femal gential tract carcinosarcomas[J].Cancer,1996,77:533—538.
8[8]Molland JG,Barraclongh BH,Gebski V,et al.Prognostic significance of C-erbB-2 oncogene in arillary node-negative breast cancer[J].Aust N I J Surg,1996,66(2):64—70.
9[9]Jennings BA,Hadfiels JE,Worsley SD,et al.A diffenrential PCR assay for the detection of c-erbB-2 amplification used in a prospective study of Breast Cancer[J].Mol Pathol,1997,50(5):254—6.
10[10]Van-Slooten HJ,Clashed PC,Van-Dierendonck JH.Expression of bcl-2 in nod-negative breast cancer is associated with various prognositic factors,but does not predict response to one course of perioperative chemotherapy[J].Br J Cancer,1996,74(1):78.
4Jemal A, Bray F, Center MM, et al. Global cancer statis- tics[J]. GA Cancer J Clin, 2011, 61(2) :69 -90.
5Chambers AF, Groom AC, Macdonald IC. Dissemination and growth of cancer cells in metastatic sites [ J ]. Nat Rev Cancer, 2002, 2 (8) : 563 - 575.
6Mostert B, Sleijfer S, Foekens JA, et al. Circulating tumor cells(ctcs) : detection methods and their clinical relevance in breast cancer [ J ]. Cancer Treat Rev, 2009, 35 (5): 463 - 474.
7Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at earch follow - up time point during therapy of meta- static breast cancer patients predict progression -free and overall survival[J]. Clin Cancer Res,2006,129 ( 14Ptl ) : 4218 - 4224.
8Cristofanilli M, Budd GT, Ellis M, et al. Circulating tumor cells,disease progression and survival in metastatic breast cancer[J]. N England J Med, 2004, 351(8) :781 -791.
9Camara O, Rengsberger M, Egbe A, et al. The relevance of circulating epithelial tumor cells(CETC) for therpy monito- ring during neoadvant ( primary systemic ) chemotherapy in breast cancer[ J ]. Ann Oncol,2007,18 (9) : 1484 - 1492.
10Jiang ZF, Cristofanilli M, Shao ZM, et al. Circulating tumor cells predict progression -free and overall survival in Chi- nese patients with metastatic breast cancer, HER2 - posi- tive or triple - negative ( CBCSG004 ) : a multicenter, double- blind, prospective trial. [ J]. Ann Oncol, 2013, 24 ( 11 ) : 2766 - 2772.
